This means that, for some patients, Wegovy is now a more cost-effective GLP-1 treatment option for weight management
Thirdly , theres also a patent application (IN202047010224) (pdf) pending by Novo Nordisk, filed in 2020 with priority date of 24/08/2017, for a specific formulation of semaglutide (the active ingredient in its commercial blockbuster drug, Ozempic) described as Semaglutide liquid formulations (no more than 0.01% (w/w) phenol. Adding to the complexity is a recent revocation petition filed by DRL in May 2025 (as reported by the media here)
Limitation of Liability: Neither MEDVi nor independent medical providers, compounding pharmacies, affiliated professional entities, or related parties can be held liable for individual treatment outcomes, medical complications, medication side effects, adverse reactions, or any consequences resulting from participation in telehealth weight loss programs
Starting then stopping due to cost wastes initial investment without gaining long-term benefits
Large trials suggest cardiovascular risk may improve with some agents, and semaglutide showed favorable cardiometabolic signals
